世界の組換え血漿タンパク質市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Recombinant Plasma Proteins Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-4799 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、96ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査レポートでは、組換え血漿タンパク質の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（チャイニーズハムスター卵巣（CHO）細胞株、ベイビーハムスター腎臓（BHK）細胞株、ヒト胎児腎臓（HEK）細胞株、その他）、用途別市場規模（血友病A、血友病B、フォンウィルブランド病、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・組換え血漿タンパク質の市場動向 ・企業の競争状況、市場シェア ・組換え血漿タンパク質の種類別市場規模と予測2016-2027（チャイニーズハムスター卵巣（CHO）細胞株、ベイビーハムスター腎臓（BHK）細胞株、ヒト胎児腎臓（HEK）細胞株、その他） ・組換え血漿タンパク質の用途別市場規模と予測2016-2027（血友病A、血友病B、フォンウィルブランド病、その他） ・組換え血漿タンパク質の北米市場規模2016-2027（アメリカ、カナダ） ・組換え血漿タンパク質の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・組換え血漿タンパク質のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・組換え血漿タンパク質の中南米市場規模2016-2027（メキシコ、ブラジル） ・組換え血漿タンパク質の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（CSL Limited、Shire (Takeda Pharmaceutical Company Limited)、Octapharma、Novo Nordisk、Bayer、Bioverativ Therapeutics, Inc. (Sanofi)、Aptevo Therapeutics、Pharming Group、Pfizer） ・結論

For almost 50 years, the fractionation of human plasma has been the sole possible source of a wide range of therapeutic proteins–such as coagulation factors, anticoagulants, immunoglobulins, and albumin–essential to the treatment of serious congenital or acquired bleeding or immunological diseases. In the last 20 years, the application of recombinant technologies to mammalian cell cultures has made possible–although with some limitations in productivity, costs, and immunogenic risks-

Market Analysis and Insights: Global Recombinant Plasma Proteins Market
The global Recombinant Plasma Proteins market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Recombinant Plasma Proteins market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Recombinant Plasma Proteins market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Recombinant Plasma Proteins market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Recombinant Plasma Proteins market.

Global Recombinant Plasma Proteins Scope and Market Size
Recombinant Plasma Proteins market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Recombinant Plasma Proteins market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Chinese Hamster Ovary (CHO) Cell Line
Baby Hamster Kidney (BHK) Cell Line
Human Embryonic Kidney (HEK) Cell Line
Others

Segment by Application
Hemophilia A
Hemophilia B
Von Willebrand Disease
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
CSL Limited
Shire (Takeda Pharmaceutical Company Limited)
Octapharma
Novo Nordisk
Bayer
Bioverativ Therapeutics, Inc. (Sanofi)
Aptevo Therapeutics
Pharming Group
Pfizer

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Recombinant Plasma Proteins Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Chinese Hamster Ovary (CHO) Cell Line
1.2.3 Baby Hamster Kidney (BHK) Cell Line
1.2.4 Human Embryonic Kidney (HEK) Cell Line
1.2.5 Others
1.3 Market by Application
1.3.1 Global Recombinant Plasma Proteins Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hemophilia A
1.3.3 Hemophilia B
1.3.4 Von Willebrand Disease
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Recombinant Plasma Proteins Market Perspective (2016-2027)
2.2 Recombinant Plasma Proteins Growth Trends by Regions
2.2.1 Recombinant Plasma Proteins Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Recombinant Plasma Proteins Historic Market Share by Regions (2016-2021)
2.2.3 Recombinant Plasma Proteins Forecasted Market Size by Regions (2022-2027)
2.3 Recombinant Plasma Proteins Industry Dynamic
2.3.1 Recombinant Plasma Proteins Market Trends
2.3.2 Recombinant Plasma Proteins Market Drivers
2.3.3 Recombinant Plasma Proteins Market Challenges
2.3.4 Recombinant Plasma Proteins Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Recombinant Plasma Proteins Players by Revenue
3.1.1 Global Top Recombinant Plasma Proteins Players by Revenue (2016-2021)
3.1.2 Global Recombinant Plasma Proteins Revenue Market Share by Players (2016-2021)
3.2 Global Recombinant Plasma Proteins Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Recombinant Plasma Proteins Revenue
3.4 Global Recombinant Plasma Proteins Market Concentration Ratio
3.4.1 Global Recombinant Plasma Proteins Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Recombinant Plasma Proteins Revenue in 2020
3.5 Recombinant Plasma Proteins Key Players Head office and Area Served
3.6 Key Players Recombinant Plasma Proteins Product Solution and Service
3.7 Date of Enter into Recombinant Plasma Proteins Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Recombinant Plasma Proteins Breakdown Data by Type
4.1 Global Recombinant Plasma Proteins Historic Market Size by Type (2016-2021)
4.2 Global Recombinant Plasma Proteins Forecasted Market Size by Type (2022-2027)

5 Recombinant Plasma Proteins Breakdown Data by Application
5.1 Global Recombinant Plasma Proteins Historic Market Size by Application (2016-2021)
5.2 Global Recombinant Plasma Proteins Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Recombinant Plasma Proteins Market Size (2016-2027)
6.2 North America Recombinant Plasma Proteins Market Size by Type
6.2.1 North America Recombinant Plasma Proteins Market Size by Type (2016-2021)
6.2.2 North America Recombinant Plasma Proteins Market Size by Type (2022-2027)
6.2.3 North America Recombinant Plasma Proteins Market Size by Type (2016-2027)
6.3 North America Recombinant Plasma Proteins Market Size by Application
6.3.1 North America Recombinant Plasma Proteins Market Size by Application (2016-2021)
6.3.2 North America Recombinant Plasma Proteins Market Size by Application (2022-2027)
6.3.3 North America Recombinant Plasma Proteins Market Size by Application (2016-2027)
6.4 North America Recombinant Plasma Proteins Market Size by Country
6.4.1 North America Recombinant Plasma Proteins Market Size by Country (2016-2021)
6.4.2 North America Recombinant Plasma Proteins Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Recombinant Plasma Proteins Market Size (2016-2027)
7.2 Europe Recombinant Plasma Proteins Market Size by Type
7.2.1 Europe Recombinant Plasma Proteins Market Size by Type (2016-2021)
7.2.2 Europe Recombinant Plasma Proteins Market Size by Type (2022-2027)
7.2.3 Europe Recombinant Plasma Proteins Market Size by Type (2016-2027)
7.3 Europe Recombinant Plasma Proteins Market Size by Application
7.3.1 Europe Recombinant Plasma Proteins Market Size by Application (2016-2021)
7.3.2 Europe Recombinant Plasma Proteins Market Size by Application (2022-2027)
7.3.3 Europe Recombinant Plasma Proteins Market Size by Application (2016-2027)
7.4 Europe Recombinant Plasma Proteins Market Size by Country
7.4.1 Europe Recombinant Plasma Proteins Market Size by Country (2016-2021)
7.4.2 Europe Recombinant Plasma Proteins Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Recombinant Plasma Proteins Market Size (2016-2027)
8.2 Asia-Pacific Recombinant Plasma Proteins Market Size by Type
8.2.1 Asia-Pacific Recombinant Plasma Proteins Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Recombinant Plasma Proteins Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Recombinant Plasma Proteins Market Size by Type (2016-2027)
8.3 Asia-Pacific Recombinant Plasma Proteins Market Size by Application
8.3.1 Asia-Pacific Recombinant Plasma Proteins Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Recombinant Plasma Proteins Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Recombinant Plasma Proteins Market Size by Application (2016-2027)
8.4 Asia-Pacific Recombinant Plasma Proteins Market Size by Region
8.4.1 Asia-Pacific Recombinant Plasma Proteins Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Recombinant Plasma Proteins Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Recombinant Plasma Proteins Market Size (2016-2027)
9.2 Latin America Recombinant Plasma Proteins Market Size by Type
9.2.1 Latin America Recombinant Plasma Proteins Market Size by Type (2016-2021)
9.2.2 Latin America Recombinant Plasma Proteins Market Size by Type (2022-2027)
9.2.3 Latin America Recombinant Plasma Proteins Market Size by Type (2016-2027)
9.3 Latin America Recombinant Plasma Proteins Market Size by Application
9.3.1 Latin America Recombinant Plasma Proteins Market Size by Application (2016-2021)
9.3.2 Latin America Recombinant Plasma Proteins Market Size by Application (2022-2027)
9.3.3 Latin America Recombinant Plasma Proteins Market Size by Application (2016-2027)
9.4 Latin America Recombinant Plasma Proteins Market Size by Country
9.4.1 Latin America Recombinant Plasma Proteins Market Size by Country (2016-2021)
9.4.2 Latin America Recombinant Plasma Proteins Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Recombinant Plasma Proteins Market Size (2016-2027)
10.2 Middle East & Africa Recombinant Plasma Proteins Market Size by Type
10.2.1 Middle East & Africa Recombinant Plasma Proteins Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Recombinant Plasma Proteins Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Recombinant Plasma Proteins Market Size by Type (2016-2027)
10.3 Middle East & Africa Recombinant Plasma Proteins Market Size by Application
10.3.1 Middle East & Africa Recombinant Plasma Proteins Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Recombinant Plasma Proteins Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Recombinant Plasma Proteins Market Size by Application (2016-2027)
10.4 Middle East & Africa Recombinant Plasma Proteins Market Size by Country
10.4.1 Middle East & Africa Recombinant Plasma Proteins Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Recombinant Plasma Proteins Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 CSL Limited
11.1.1 CSL Limited Company Details
11.1.2 CSL Limited Business Overview
11.1.3 CSL Limited Recombinant Plasma Proteins Introduction
11.1.4 CSL Limited Revenue in Recombinant Plasma Proteins Business (2016-2021)
11.1.5 CSL Limited Recent Development
11.2 Shire (Takeda Pharmaceutical Company Limited)
11.2.1 Shire (Takeda Pharmaceutical Company Limited) Company Details
11.2.2 Shire (Takeda Pharmaceutical Company Limited) Business Overview
11.2.3 Shire (Takeda Pharmaceutical Company Limited) Recombinant Plasma Proteins Introduction
11.2.4 Shire (Takeda Pharmaceutical Company Limited) Revenue in Recombinant Plasma Proteins Business (2016-2021)
11.2.5 Shire (Takeda Pharmaceutical Company Limited) Recent Development
11.3 Octapharma
11.3.1 Octapharma Company Details
11.3.2 Octapharma Business Overview
11.3.3 Octapharma Recombinant Plasma Proteins Introduction
11.3.4 Octapharma Revenue in Recombinant Plasma Proteins Business (2016-2021)
11.3.5 Octapharma Recent Development
11.4 Novo Nordisk
11.4.1 Novo Nordisk Company Details
11.4.2 Novo Nordisk Business Overview
11.4.3 Novo Nordisk Recombinant Plasma Proteins Introduction
11.4.4 Novo Nordisk Revenue in Recombinant Plasma Proteins Business (2016-2021)
11.4.5 Novo Nordisk Recent Development
11.5 Bayer
11.5.1 Bayer Company Details
11.5.2 Bayer Business Overview
11.5.3 Bayer Recombinant Plasma Proteins Introduction
11.5.4 Bayer Revenue in Recombinant Plasma Proteins Business (2016-2021)
11.5.5 Bayer Recent Development
11.6 Bioverativ Therapeutics, Inc. (Sanofi)
11.6.1 Bioverativ Therapeutics, Inc. (Sanofi) Company Details
11.6.2 Bioverativ Therapeutics, Inc. (Sanofi) Business Overview
11.6.3 Bioverativ Therapeutics, Inc. (Sanofi) Recombinant Plasma Proteins Introduction
11.6.4 Bioverativ Therapeutics, Inc. (Sanofi) Revenue in Recombinant Plasma Proteins Business (2016-2021)
11.6.5 Bioverativ Therapeutics, Inc. (Sanofi) Recent Development
11.7 Aptevo Therapeutics
11.7.1 Aptevo Therapeutics Company Details
11.7.2 Aptevo Therapeutics Business Overview
11.7.3 Aptevo Therapeutics Recombinant Plasma Proteins Introduction
11.7.4 Aptevo Therapeutics Revenue in Recombinant Plasma Proteins Business (2016-2021)
11.7.5 Aptevo Therapeutics Recent Development
11.8 Pharming Group
11.8.1 Pharming Group Company Details
11.8.2 Pharming Group Business Overview
11.8.3 Pharming Group Recombinant Plasma Proteins Introduction
11.8.4 Pharming Group Revenue in Recombinant Plasma Proteins Business (2016-2021)
11.8.5 Pharming Group Recent Development
11.9 Pfizer
11.9.1 Pfizer Company Details
11.9.2 Pfizer Business Overview
11.9.3 Pfizer Recombinant Plasma Proteins Introduction
11.9.4 Pfizer Revenue in Recombinant Plasma Proteins Business (2016-2021)
11.9.5 Pfizer Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Recombinant Plasma Proteins Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Chinese Hamster Ovary (CHO) Cell Line
Table 3. Key Players of Baby Hamster Kidney (BHK) Cell Line
Table 4. Key Players of Human Embryonic Kidney (HEK) Cell Line
Table 5. Key Players of Others
Table 6. Global Recombinant Plasma Proteins Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Recombinant Plasma Proteins Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Recombinant Plasma Proteins Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Recombinant Plasma Proteins Market Share by Regions (2016-2021)
Table 10. Global Recombinant Plasma Proteins Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Recombinant Plasma Proteins Market Share by Regions (2022-2027)
Table 12. Recombinant Plasma Proteins Market Trends
Table 13. Recombinant Plasma Proteins Market Drivers
Table 14. Recombinant Plasma Proteins Market Challenges
Table 15. Recombinant Plasma Proteins Market Restraints
Table 16. Global Recombinant Plasma Proteins Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Recombinant Plasma Proteins Market Share by Players (2016-2021)
Table 18. Global Top Recombinant Plasma Proteins Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Recombinant Plasma Proteins as of 2020)
Table 19. Ranking of Global Top Recombinant Plasma Proteins Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Recombinant Plasma Proteins Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Recombinant Plasma Proteins Product Solution and Service
Table 23. Date of Enter into Recombinant Plasma Proteins Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Recombinant Plasma Proteins Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Recombinant Plasma Proteins Revenue Market Share by Type (2016-2021)
Table 27. Global Recombinant Plasma Proteins Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Recombinant Plasma Proteins Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Recombinant Plasma Proteins Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Recombinant Plasma Proteins Revenue Market Share by Application (2016-2021)
Table 31. Global Recombinant Plasma Proteins Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Recombinant Plasma Proteins Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Recombinant Plasma Proteins Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Recombinant Plasma Proteins Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Recombinant Plasma Proteins Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Recombinant Plasma Proteins Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Recombinant Plasma Proteins Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Recombinant Plasma Proteins Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Recombinant Plasma Proteins Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Recombinant Plasma Proteins Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Recombinant Plasma Proteins Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Recombinant Plasma Proteins Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Recombinant Plasma Proteins Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Recombinant Plasma Proteins Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Recombinant Plasma Proteins Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Recombinant Plasma Proteins Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Recombinant Plasma Proteins Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Recombinant Plasma Proteins Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Recombinant Plasma Proteins Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Recombinant Plasma Proteins Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Recombinant Plasma Proteins Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Recombinant Plasma Proteins Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Recombinant Plasma Proteins Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Recombinant Plasma Proteins Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Recombinant Plasma Proteins Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Recombinant Plasma Proteins Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Recombinant Plasma Proteins Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Recombinant Plasma Proteins Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Recombinant Plasma Proteins Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Recombinant Plasma Proteins Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Recombinant Plasma Proteins Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Recombinant Plasma Proteins Market Size by Country (2022-2027) & (US$ Million)
Table 63. CSL Limited Company Details
Table 64. CSL Limited Business Overview
Table 65. CSL Limited Recombinant Plasma Proteins Product
Table 66. CSL Limited Revenue in Recombinant Plasma Proteins Business (2016-2021) & (US$ Million)
Table 67. CSL Limited Recent Development
Table 68. Shire (Takeda Pharmaceutical Company Limited) Company Details
Table 69. Shire (Takeda Pharmaceutical Company Limited) Business Overview
Table 70. Shire (Takeda Pharmaceutical Company Limited) Recombinant Plasma Proteins Product
Table 71. Shire (Takeda Pharmaceutical Company Limited) Revenue in Recombinant Plasma Proteins Business (2016-2021) & (US$ Million)
Table 72. Shire (Takeda Pharmaceutical Company Limited) Recent Development
Table 73. Octapharma Company Details
Table 74. Octapharma Business Overview
Table 75. Octapharma Recombinant Plasma Proteins Product
Table 76. Octapharma Revenue in Recombinant Plasma Proteins Business (2016-2021) & (US$ Million)
Table 77. Octapharma Recent Development
Table 78. Novo Nordisk Company Details
Table 79. Novo Nordisk Business Overview
Table 80. Novo Nordisk Recombinant Plasma Proteins Product
Table 81. Novo Nordisk Revenue in Recombinant Plasma Proteins Business (2016-2021) & (US$ Million)
Table 82. Novo Nordisk Recent Development
Table 83. Bayer Company Details
Table 84. Bayer Business Overview
Table 85. Bayer Recombinant Plasma Proteins Product
Table 86. Bayer Revenue in Recombinant Plasma Proteins Business (2016-2021) & (US$ Million)
Table 87. Bayer Recent Development
Table 88. Bioverativ Therapeutics, Inc. (Sanofi) Company Details
Table 89. Bioverativ Therapeutics, Inc. (Sanofi) Business Overview
Table 90. Bioverativ Therapeutics, Inc. (Sanofi) Recombinant Plasma Proteins Product
Table 91. Bioverativ Therapeutics, Inc. (Sanofi) Revenue in Recombinant Plasma Proteins Business (2016-2021) & (US$ Million)
Table 92. Bioverativ Therapeutics, Inc. (Sanofi) Recent Development
Table 93. Aptevo Therapeutics Company Details
Table 94. Aptevo Therapeutics Business Overview
Table 95. Aptevo Therapeutics Recombinant Plasma Proteins Product
Table 96. Aptevo Therapeutics Revenue in Recombinant Plasma Proteins Business (2016-2021) & (US$ Million)
Table 97. Aptevo Therapeutics Recent Development
Table 98. Pharming Group Company Details
Table 99. Pharming Group Business Overview
Table 100. Pharming Group Revenue in Recombinant Plasma Proteins Business (2016-2021) & (US$ Million)
Table 101. Pharming Group Recent Development
Table 102. Pfizer Company Details
Table 103. Pfizer Business Overview
Table 104. Pfizer Recombinant Plasma Proteins Product
Table 105. Pfizer Revenue in Recombinant Plasma Proteins Business (2016-2021) & (US$ Million)
Table 106. Pfizer Recent Development
Table 107. Research Programs/Design for This Report
Table 108. Key Data Information from Secondary Sources
Table 109. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Recombinant Plasma Proteins Market Share by Type: 2020 VS 2027
Figure 2. Chinese Hamster Ovary (CHO) Cell Line Features
Figure 3. Baby Hamster Kidney (BHK) Cell Line Features
Figure 4. Human Embryonic Kidney (HEK) Cell Line Features
Figure 5. Others Features
Figure 6. Global Recombinant Plasma Proteins Market Share by Application: 2020 VS 2027
Figure 7. Hemophilia A Case Studies
Figure 8. Hemophilia B Case Studies
Figure 9. Von Willebrand Disease Case Studies
Figure 10. Others Case Studies
Figure 11. Recombinant Plasma Proteins Report Years Considered
Figure 12. Global Recombinant Plasma Proteins Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 13. Global Recombinant Plasma Proteins Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Recombinant Plasma Proteins Market Share by Regions: 2020 VS 2027
Figure 15. Global Recombinant Plasma Proteins Market Share by Regions (2022-2027)
Figure 16. Global Recombinant Plasma Proteins Market Share by Players in 2020
Figure 17. Global Top Recombinant Plasma Proteins Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Recombinant Plasma Proteins as of 2020
Figure 18. The Top 10 and 5 Players Market Share by Recombinant Plasma Proteins Revenue in 2020
Figure 19. Global Recombinant Plasma Proteins Revenue Market Share by Type (2016-2021)
Figure 20. Global Recombinant Plasma Proteins Revenue Market Share by Type (2022-2027)
Figure 21. North America Recombinant Plasma Proteins Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. North America Recombinant Plasma Proteins Market Share by Type (2016-2027)
Figure 23. North America Recombinant Plasma Proteins Market Share by Application (2016-2027)
Figure 24. North America Recombinant Plasma Proteins Market Share by Country (2016-2027)
Figure 25. United States Recombinant Plasma Proteins Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Canada Recombinant Plasma Proteins Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Recombinant Plasma Proteins Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Recombinant Plasma Proteins Market Share by Type (2016-2027)
Figure 29. Europe Recombinant Plasma Proteins Market Share by Application (2016-2027)
Figure 30. Europe Recombinant Plasma Proteins Market Share by Country (2016-2027)
Figure 31. Germany Recombinant Plasma Proteins Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. France Recombinant Plasma Proteins Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. U.K. Recombinant Plasma Proteins Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Italy Recombinant Plasma Proteins Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Russia Recombinant Plasma Proteins Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Nordic Recombinant Plasma Proteins Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Recombinant Plasma Proteins Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Recombinant Plasma Proteins Market Share by Type (2016-2027)
Figure 39. Asia-Pacific Recombinant Plasma Proteins Market Share by Application (2016-2027)
Figure 40. Asia-Pacific Recombinant Plasma Proteins Market Share by Region (2016-2027)
Figure 41. China Recombinant Plasma Proteins Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Japan Recombinant Plasma Proteins Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. South Korea Recombinant Plasma Proteins Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Southeast Asia Recombinant Plasma Proteins Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. India Recombinant Plasma Proteins Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Australia Recombinant Plasma Proteins Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Recombinant Plasma Proteins Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Recombinant Plasma Proteins Market Share by Type (2016-2027)
Figure 49. Latin America Recombinant Plasma Proteins Market Share by Application (2016-2027)
Figure 50. Latin America Recombinant Plasma Proteins Market Share by Country (2016-2027)
Figure 51. Mexico Recombinant Plasma Proteins Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Brazil Recombinant Plasma Proteins Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Recombinant Plasma Proteins Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Recombinant Plasma Proteins Market Share by Type (2016-2027)
Figure 55. Middle East & Africa Recombinant Plasma Proteins Market Share by Application (2016-2027)
Figure 56. Middle East & Africa Recombinant Plasma Proteins Market Share by Country (2016-2027)
Figure 57. Turkey Recombinant Plasma Proteins Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Saudi Arabia Recombinant Plasma Proteins Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. UAE Recombinant Plasma Proteins Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. CSL Limited Revenue Growth Rate in Recombinant Plasma Proteins Business (2016-2021)
Figure 61. Shire (Takeda Pharmaceutical Company Limited) Revenue Growth Rate in Recombinant Plasma Proteins Business (2016-2021)
Figure 62. Octapharma Revenue Growth Rate in Recombinant Plasma Proteins Business (2016-2021)
Figure 63. Novo Nordisk Revenue Growth Rate in Recombinant Plasma Proteins Business (2016-2021)
Figure 64. Bayer Revenue Growth Rate in Recombinant Plasma Proteins Business (2016-2021)
Figure 65. Bioverativ Therapeutics, Inc. (Sanofi) Revenue Growth Rate in Recombinant Plasma Proteins Business (2016-2021)
Figure 66. Aptevo Therapeutics Revenue Growth Rate in Recombinant Plasma Proteins Business (2016-2021)
Figure 67. Pharming Group Revenue Growth Rate in Recombinant Plasma Proteins Business (2016-2021)
Figure 68. Pfizer Revenue Growth Rate in Recombinant Plasma Proteins Business (2016-2021)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed

---